John M. Kirkwood, MD, on Melanoma: Early Study Results on Vidutolimod and Pembrolizumab

December 03, 2021 By The ASCO Post Staff

John M. Kirkwood, MD, of the University of Pittsburgh Medical Center, discusses phase Ib findings on the combination of vidutolimod plus pembrolizumab, as well as vidutolimod monotherapy, both of which showed clinical activity in patients with PD-1 blockade–refractory melanoma. The duration of response with the combination therapy was substantially longer. Phase II studies are ongoing (Abstract 950).

Related Content